

Assistant Commissioner for Patents
Washington, D.C. 20231

Atty. Dkt.: 1721-44

Date: January 7, 2002

Sir:

Attached for filing is the patent application of:

Inventor: Moretta et al

Entitled: NOVEL TRIGGERING RECEPTOR INVOLVED IN NATURAL
CYTOTOXICITY MEDIATED BY HUMAN NATURAL KILLER
CELLS AND ANTIBODIES THAT IDENTIFY THE SAME

and including attachments as noted below:

- ☐ Newly executed Declaration, ☒ Copy of Declaration from prior application, ☒ Abstract
54 pages of specification and claims (including 21 numbered claims), and
19 sheets of accompanying drawing/s.
☐ Record the attached assignment and return to the undersigned.
☐ Attached is a Power of Attorney.
☐ Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:

Application Number

Country

Day/Month/Year Filed



, respectively, the entire content of which is hereby incorporated by reference in this application..

- ☐ Certified copy(ies) of foreign application(s) is/are attached.
☐ Certified copy(ies) filed on _____ in prior appln. no. _____ filed _____
☐ Please amend the specification by inserting the following paragraph before the first line: --This application claims the benefit of Provisional Application No. _____, filed _____, the entire content of which is hereby incorporated by reference in this application.--
☒ Please amend the specification by inserting the following paragraph before the first line: --This application is a ☐ continuation/☒ division/☐ continuation-in-part of Application No. 09/440,514, filed November 15, 1999, _____, the entire content of which is hereby incorporated by reference in this application.--
☒ Petition filed in prior application to extend its life to insure co-pendency.
☒ The prior application is assigned to Università di Genova and Innate Pharma S.A.S. .
☒ It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached.
☐ Applicant claims "small entity" status. ☐ "Small entity" statement attached.
☒ Please enter the attached and/or below preliminary amendment prior to calculation of filing fee:

- ☒ Also attached: ☒ Information Disclosure Statement; ☐ Non-Publication Request; ☒ Nucleotide and/or Amino Acid Sequence Submission; ☐ Statement deleting Inventor(s) named in prior application; ☒ Other: Statement re Sequence Listing; Request

FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED

Basic Filing Fee				\$	740.00
Total effective claims	21	- 20 (at least 20) =	1	x \$ 18.00	\$ 18.00
Independent claims	3	- 3 (at least 3) =	0	x \$ 84.00	\$ 0.00
If any proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)				\$	0.00
				SUBTOTAL	\$ 758.00
If "small entity," then enter half (1/2) of subtotal and subtract				-(0.00)
				SECOND SUBTOTAL	\$ 758.00
Assignment Recording Fee (\$40.00)				\$	0.00
				TOTAL FEE ENCLOSED	\$ 758.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:eaw

NIXON & VANDERHYTE P.C.

By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: _____

B. J. Sadoff

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

DIVISIONAL OF SERIAL NO.

1721-44

09/440,514

APPLICANT

MORETTA et al.

FILING DATE

GROUP

January 7, 2002

Unassigned

(Use several sheets if necessary)

 JC832 U.S. PTO
 10/036444
 01/07/02

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Nalabolu et al., 1996, Genomics 31 :215-222
	Moretta, A., Cell, 1997, July 11; 90(1) :13-8
	Genbank November 1997, 1C7 sequence, accession number AF 031138
	Sivori, S. et al., J. Exp. Med. 1997 Oct. 6; 186(7) :1129-36
	Moretta, A. et al., Eur. J. Immunogenet. 1997 Dec.; 24(6) :455-68
	Moretta, A., et al., Curr. Top Microbiol. Immunol. 1998; 230 :15-23
	Vitale, M., et al., J. Exp. Med. 1998 June 15; 187(12) :2065-72
	Poccia, F. et al., Immunol. Today, 1998 June; 19(6) :253-6
	Pessino, A., et al., J. Exp. Med., 1998 September 7; 188(5) :953-60
	Cantoni, C., et al., J. Exp. Med. 1999 March 1; 189(5) :787-96
	Biassoni, R. et al., Eur. J. Immunol., 1999 March; 29(3) :1014-20
	Biassoni, R. et al., Semin. Cancer Biol., 1999 February; 9(1) :13-8
	Sivori, S. et al., Eur. J. Immunol., 1999 May; 29(5) :1656-66
	Falco, M. et al., Immunol. Lett., 1999 June 1; 68(2-3) :411-4
	Neville, M.J. and Campbell, R.D., 1999, J. Immunol. 162 :4745-4754
	Moretta, A. et al., Curr. Top. Microbiol. Immunol., 1999; 244 :69-84
	Genbank disclosure on AJ 223153 sequence
	Ngo et al, in The Protein Folding Problem and Tertiary Structure ..., 1994, Merz et al (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
	Skolnick et al, From genes to protein structure and function: novel applications ..., Jan 2000, Trends in Biotech. 18(1):34-39.
	Attwood et al, The babel of bioinformatics, Oct 2000, Science 290 (5491):471-473.
	Mikayama et al, Molecular cloning and functional expression of cDNA ..., Nov 1993, Proc. Natl. Acad. Sci., USA, Vol. 90: 10056-10060.
	Voet et al, Biochemistry I, 1990, pages 126-234.
	Kuby et al, 1994, Immunology, Second edition, pages 85-96.
	Colman et al, Effects of amino acid sequence changes ..., 1994, A structural view of immune recognition by antibodies, pages 33-36.
	Nalabolu et al, Accession 014932, Jan. 1998.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)